uzansertib (INCB53914) / Incyte  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
uzansertib (INCB53914) / Incyte
NCT03688152: A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

Completed
1b
9
US
INCB053914, INCB050465
Incyte Corporation
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
09/20
09/20
NCT04355039: INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Withdrawn
1
0
NA
Pomalidomide, Pomalyst, Dexamethasone, Ozurdex, INCB053914 50 mg bis in die (BID), pan-PIM Kinase Inhibitor, INCB053914 65 mg BID, INCB053914 80 mg BID
Medical College of Wisconsin
Refractory Multiple Myeloma, Relapse Multiple Myeloma
07/23
07/24

Download Options